Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-622-4003
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees35
OptionableOptionable
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.02. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
6 equities research analysts have issued 1 year target prices for Zafgen's stock. Their forecasts range from $4.52 to $20.00. On average, they anticipate Zafgen's stock price to reach $14.13 in the next year. This suggests a possible upside of 216.1% from the stock's current price. View Analyst Price Targets for Zafgen.
What is the consensus analysts' recommendation for Zafgen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zafgen.
Has Zafgen been receiving favorable news coverage?
News stories about ZFGN stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zafgen earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include Ra Pharmaceuticals (RARX), Revance Therapeutics (RVNC), Rocket Pharmaceuticals (RCKT), Viking Therapeutics (VKTX), Vectura Group (VEGPF), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Assembly Biosciences (ASMB), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), Kura Oncology (KURA), Karyopharm Therapeutics (KPTI) and Aurinia Pharmaceuticals (AUPH).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
- Dr. Thomas E. Hughes, Pres & Chief Scientific Officer (Age 59)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
- Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
Who are Zafgen's major shareholders?
Zafgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Great Point Partners LLC (9.76%), Atlas Venture Advisors Inc. (9.51%), BlackRock Inc. (7.04%), 683 Capital Management LLC (3.80%), Dimensional Fund Advisors LP (2.45%) and Artal Group S.A. (1.90%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.
Which major investors are selling Zafgen stock?
ZFGN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, D. E. Shaw & Co. Inc., Royce & Associates LP, Artal Group S.A., Sphera Funds Management LTD., Algert Global LLC and Private Advisor Group LLC. View Insider Buying and Selling for Zafgen.
Which major investors are buying Zafgen stock?
ZFGN stock was purchased by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc., BlackRock Inc., Great Point Partners LLC, Hikari Power Ltd, 683 Capital Management LLC, GSA Capital Partners LLP, Candriam Luxembourg S.C.A. and Squarepoint Ops LLC. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim and Frances K Heller. View Insider Buying and Selling for Zafgen.
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $4.47.
How big of a company is Zafgen?
Zafgen has a market capitalization of $164.81 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
What is Zafgen's official website?
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
